<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613963</url>
  </required_header>
  <id_info>
    <org_study_id>12DEV0010</org_study_id>
    <nct_id>NCT01613963</nct_id>
  </id_info>
  <brief_title>Causes of Visual Loss in Retinal Disease</brief_title>
  <official_title>Observational Study of Visual Outcomes in Retinal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Surrey County Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Surrey County Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of visual outcomes in retinal disease that seeks to identify the causes of
      visual loss. This data will be used to predict which patients are at risk of losing vision
      and how they can be better treated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study of visual outcomes in retinal disease. It is an observational study of
      patients who have been seen in the retinal clinic, and involves a retrospective casenotes
      analysis to identify patients who have suffered visual loss and the reason for that visual
      loss. These data will be analysed to enable the identification of factors that predict visual
      loss in patients who present earlier in the course of their disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity at 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>Best-corrected visual acuity at 5 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity at 10 years</measure>
    <time_frame>10 years</time_frame>
    <description>Best corrected visual acuity at 10 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Source of referral</measure>
    <time_frame>Baseline</time_frame>
    <description>Categorised as A&amp;E/GP referral/Optician referral/Tertiary referral</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laterality</measure>
    <time_frame>Baseline</time_frame>
    <description>Categorised as:
Right eye/Left eye/Bilateral</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomical diagnosis</measure>
    <time_frame>Baseline</time_frame>
    <description>Cateogorised as:
Acute anterior uveitis / Chronic anterior uveitis / Fuchs heterochromic cyclitis / Intermediate uveitis / Pars planitis / Posterior Uveitis / Panuveitis / Episcleritis / Scleritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aetiological diagnosis</measure>
    <time_frame>Baseline</time_frame>
    <description>Diagnosed as:
Viral / Bacterial / Fungal / Parasitic / Inflammatory / Malignant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Associated systemic disease</measure>
    <time_frame>Baseline</time_frame>
    <description>Any associated systemic disease, e.g. HLA-B27 associated disease, Behcet's disease, multiple sclerosis, Vogt-Koyanagi-Harada syndrome, rheumatoid arthritis, collagen vascular disease, tuberculosis, granulomatosis with polyangiitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of disease and causes of visual loss at 5 years</measure>
    <time_frame>5 years</time_frame>
    <description>Categorised into:
Corneal clarity problems / cataract / vitreous debris / retinal detachment / cystoid macular edema / retinal pigment epithelium atrophy / macular scarring / epiretinal membrane / macular hole / steroid response / glaucoma / other optic neuropathy / hypotony &amp; phthisis / other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of disease and causes of visual loss at 10 years</measure>
    <time_frame>10 years</time_frame>
    <description>Categorised into:
Corneal clarity problems / cataract / vitreous debris / retinal detachment / cystoid macular edema / retinal pigment epithelium atrophy / macular scarring / epiretinal membrane / macular hole / steroid response / glaucoma / other optic neuropathy / hypotony &amp; phthisis / other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of disease and causes of visual loss</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Categorised into:
Corneal clarity problems / cataract / vitreous debris / retinal detachment / cystoid macular edema / retinal pigment epithelium atrophy / macular scarring / epiretinal membrane / macular hole / steroid response / glaucoma / other optic neuropathy / hypotony &amp; phthisis / other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment measures employed</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Categorised into:
Topical treatment / periocular steroid / intraocular steroid / intraocular other agent / Glaucoma treatment / systemic immunosuppressive agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of disease and treatment</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Categorised into:
Local complications: Raised intraocular pressure / cataract / endophthalmitis / other
Systemic complications: Diabetes / hypertension / cholesterol / liver function / bone density loss / other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical procedures</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>List and dates of any intraocular surgery performed during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of disease - appointments</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Number of outpatient appointments over the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of disease - outpatient procedures</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Number of outpatient procedures over the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of disease - inpatient procedures</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Number of inpatient procedures over the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blind registration</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Year of any registration as partially sighted or blind</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Uveitis</condition>
  <condition>Scleritis</condition>
  <arm_group>
    <arm_group_label>Patients with ocular inflammation</arm_group_label>
    <description>Patients with ocular inflammation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunosuppressive Agents</intervention_name>
    <description>Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs</description>
    <arm_group_label>Patients with ocular inflammation</arm_group_label>
    <other_name>Prednisolone</other_name>
    <other_name>Azathioprine</other_name>
    <other_name>Methotrexate</other_name>
    <other_name>Mycophenolate mofetil</other_name>
    <other_name>Cyclosporine A</other_name>
    <other_name>Infliximab</other_name>
    <other_name>Adalimumab</other_name>
    <other_name>Etanercept</other_name>
    <other_name>Rituximab</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ocular inflammation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a diagnosis of ocular inflammation

          -  patients with at least 6 months of follow-up

        Exclusion Criteria:

          -  patients without a diagnosis of ocular inflammation

          -  patients with less than 6 months of follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon RJ Taylor, PhD FRCOphth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Surrey County Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>UK</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>June 5, 2012</last_update_submitted>
  <last_update_submitted_qc>June 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Surrey County Hospital</investigator_affiliation>
    <investigator_full_name>Simon Taylor</investigator_full_name>
    <investigator_title>Senior Lecturer &amp; Consultant Ophthalmic Surgeon</investigator_title>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <keyword>Scleritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Scleritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

